The utility of a nebulised intra-tracheal rat model of invasive pulmonary aspergillosis

Mycoses

Volumn 52, Issue 3, 2009, Pages 239-245

  Chandenier, J ^a,b   Bernard, S ^c,d   Montharu, J ^d   Bailly, E ^a   Fetissof, F ^a   De Monte, M ^d   Desoubeaux, G ^a   Diot, P ^a,b,d   Richard Lenoble, D ^a  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b INSERM   (France)

^c CEMAGREF   (France)

^d IFR 135   (France)

Author keywords

Aerosolisation; Animal model; Aspergillosis; Rat

Indexed keywords

CYCLOPHOSPHAMIDE; ISOFLURANE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; HISTOPATHOLOGY; INFECTION SENSITIVITY; LUNG ASPERGILLOSIS; MALE; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RAT; REPRODUCIBILITY; WEIGHT CHANGE;

ANIMALS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; HUMANS; INVASIVE PULMONARY ASPERGILLOSIS; MALE; NEBULIZERS AND VAPORIZERS; RATS; RATS, SPRAGUE-DAWLEY; SPORES, FUNGAL; TRACHEA;

ANIMALIA; ASPERGILLUS; ASPERGILLUS FUMIGATUS; RATTUS;

EID: 63849114023     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01695.x     Document Type: Article

References (26)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998 26 : 781 803.
2. Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999 12 : 310 50.
3. Polak A. Experimental models in antifungal chemotherapy. Mycoses 1998 41 : 1 30.
4. Clemons KV, Stevens DA. The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med Mycol 2005 43 : S101 10.
5. Lewis RE, Wiederhold NP. Murine model of invasive aspergillosis. Methods Mol Med 2005 118 : 129 42.
6. Sheppard DC, Rieg G, Chiang LY et al. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2004 47 : 1908 11.
7. Steinbach WJ, Benjamin DK Jr., Trasi SA et al. Value of an inhalational model of invasive aspergillosis. Med Mycol 2004 42 : 417 25.
8. Patterson TF. The future of animal models of invasive aspergillosis. Med Mycol 2005 43 : S115 9.
9. Schmitt HJ, Bernard EM, Hauser M et al. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988 32 : 1676 9.
10. Leenders ACAP, de Marie S, ten Kate MT et al. Liposomal amphotericin B (Ambisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis. J Antimicrob Chemother 1996 38 : 215 25.
11. Kurtz MB, Bernard EM, Edwards FF et al. Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1995 39 : 1784 9.
12. Murphy M, Bernard EM, Ishimaru T et al. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997 41 : 696 8.
13. Becker MJ, de Marie S, Fens MHAM et al. Enhanced antifungal efficacy in experimental invasive pulmonary aspergillosis by combination of Ambisome with Fungizone as assessed by several parameters of antifungal response. J Antimicrob Chemother 2002 49 : 813 20.
14. Becker MJ, de Marie S, Willemse D et al. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol 2000 38 : 1434 8.
15. 99mTc-labeled PEG liposomes allows early detection of experimental invasive pulmonary aspergillosis in neutropenic rats. Nucl Med Biol 2002 29 : 177 84.
16. Becker MJ, de Marie S, Fens MHAM et al. Pathophysiology of unilateral pulmonary aspergillosis in an experimental rat model. Med Mycol 2006 44 : 133 9.
17. Diehl KH, Hull R, Morton D et al. A good practice guide to the administration of substances and removal of blood, including routes and volumes. J Appl Toxicol 2001 21 : 15 23.
18. Kobzik L. Lung macrophage uptake of unopsonized environmental particulates, role of scavenger-types receptors. J Immunol 1995 115 : 367 76.
19. Garcia-Contreras L, Sarubbi D, Flanders E et al. Immediate and short-term cellular and biochemical responses to pulmonary single-dose studies of insulin and H-MAP. Pharm Res 2001 18 : 1685 93.
20. Soubani AO, Chandrasekar PH. The clinical spectrum of pulmonary aspergillosis. Chest 2002 121 : 1988 99.
21. Maertens J, Theunissen K, Verhoef G et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005 41 : 1242 50.
22. Schmidt A. Animal models of aspergillosis - also useful for vaccination strategies? Mycoses 2002 45 : 38 40.
23. Martin MT, Gavalda J, Lopez P et al. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. J Antimicrob Chemother 2003 52 : 1032 4.
24. Balloy V, Huerre M, Latgé JP et al. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005 73 : 494 503.
25. Kawazu M, Kanda Y, Nannya Y et al. Prospective comparison of the diagnostic potential of real-time PCR, double-sandwich enzyme-linked immunosorbent assay for galactomannan, and a (1→3)-beta-D-glucan test in weekly screening for invasive aspergillosis in patients with hematological disorders. J Clin Microbiol 2004 42 : 2733 41.
26. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis 2006 42 : 487 9.